Vaccines are being developed around the world to prevent the new corona virus, and in recent days several companies have released positive results.
But there is growing evidence that the current vaccines may be useful in treating coronavirus-related diseases, even though they have not been developed.
One of them is the MMR (measles, mumps, rubella or German measles) vaccine, which has been working since July this year to test its effectiveness against code 19.
Researchers have now presented further evidence that the antibodies produced by the use of this vaccine protect patients with the serious severity of code 19 disease who have been treated with the MMR2 vaccine. ۔
The MMR2 vaccine used the Measles Edmonton type, Memphis’ Geral Lennon (B level) type and Rabiola’s Wester RA 27/3 type.
“We found that people under the age of 42 who used the MMR vaccine 2 were more likely to be involved in the severity of code 19,” said researchers involved in the study, which was published in the medical journal M Bio.
Read More:G20 countries announce measures for transparent distribution of corona vaccine worldwide
He said the findings reinforce the notion that the MMR vaccine could potentially protect against code 19 and that the rate of cases of the disease in children is higher than in adults. Why am I so short?
He said that most children are vaccinated at the age of 12 to 15 months and the second time at the age of 4 to 6 years.
For this study, researchers divided 80 people into 2 groups.
One was a group of 50 people with MMR2 and the other group of 3 people who had no history of MMR2 vaccination but had MMR antibodies to other sources including measles, mumps or rubella. Be made of
The researchers found a significant correlation in the severity of code 19 in individuals in the MMR2 group, but no such correlation was observed in the other group.
The severity of mumps antibodies in the MMR2 group will be 134 to 300 AU / mL in individuals who were immune or asymptomatic.
In contrast, the rate of these antibodies was 134 AU / mL in patients with mild symptoms of COD-19 and less than 75 AU / mL in people with mild symptoms.
Read More:Russia ready to provide corona vaccine to countries in need
The rate was less than 32 AU / mL in people who had high severity of code 19 and were hospitalized where they needed oxygen.
The researchers said this was the first immunological study to examine the relationship between the MMR2 vaccine and Code 19.
“Statistics show that there is a strong link between mumps antibodies and code 19 and there should be more research,” he said.
He said that MMR2 is considered a safe vaccine with very few side effects and if it can be useful or effective in preventing and spreading code 19, it would be an excellent tool.
Earlier in July, a study found that the vaccine could reduce the risk of severe inflammation and death in patients with COD 19.
Research reports have shown that such vaccines also protect against other diseases by ‘training’ the immune system.
These vaccines help with the unconventional immune response and are the first defense against the disease.
Dr. Paul Fidel Jr., associate dean of the Louisiana State University Health School of Dentistry, who conducted the study in July, said such vaccines not only boost immunity against certain germs but also provide unconventional benefits.
Dr. Paul Fidel worked with Dr. Marie Nower, a professor of microbiology and immunology at Tolan University of Medicine, and the results showed that these vaccines protect a type of immune cell through MDSC.
Medical experts have shown in experiments on mice that these cells reduce the risk of inflammation and death from a disease, while the new study also found that such vaccines also infect infections with MDSC. Possible protection can be found.
The researchers said that an MMR vaccine could help fight lung inflammation and infection by including MDSC cells in people infected with code 19, a common problem in severe cases of the disease.
Read More:Pakistan has allocated 100 million for the purchase of Covid 19 vaccine
As proof of this, he presented 955 USS Roosevelt sailors as a test case in which Code 19 was confirmed but its severity was mild.
The researchers said that this was probably because all people in the US Navy underwent MMR vaccination, but their age and physical fitness were also factors in their recovery.
Other evidence supports a link between the MMR vaccine and Code 19. The data revealed that people living in areas where the MMR vaccine is common have a lower mortality rate than Code 19. Gone
Code 19 is also a potentially less contagious disease for children and is also caused by vaccinations, meaning that vaccines such as TB or MMR are likely to play a role in protecting children.